Monograph Details
|
|
Neoplasms
> Antimetabolites
|
|
HYDREA |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Substituted urea. |
| Generic Name |
|
Hydroxyurea 500mg; caps. |
| Indications |
|
Melanoma, recurrent metastatic or inoperable ovarian carcinoma, resistant chronic myelocytic leukemia, adjunct with irradiation therapy in primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. |
| Children |
|
Not recommended. |
| Adults |
|
See literature. Concomitant irradiation for carcinomas of head and neck, and intermittant therapy for solid tumors: 80mg/kg as single dose every 3rd day. Continuous therapy for solid tumors, and resistant chronic myelocytic leukemia: 20–30mg/kg/day as single dose. Renal impairment: reduce dose. |
| Contraindications |
|
Marked bone marrow depression. |
| Precautions |
|
Correct anemia before starting. Monitor blood, bone marrow, liver, and kidney function before and during treatment. Myeloproliferative disorders. Marked renal dysfunction. Discontinue if cutaneous vasculitic ulcerations develop. Elderly. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
Myelosuppressives potentiate antineoplastic effect. May antagonize antigout agents. Increased risk of vasculitic toxicities with interferon therapy. |
| Adverse Reactions |
|
Leukopenia, anemia, erythrocytic abnormalities, thrombocytopenia, GI upset, rash, erythema, fever, CNS effects, temporary renal impairment, cutaneous vasculitic toxicities (eg, ulcerations, gangrene). |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
